1. In Vivo
  2. >>Outlook

Outlook 2025: Will Geopolitics Dampen Pharma’s Comeback Party?

 
• By Jo Shorthouse

The financial macroenvironment may be looking more favorable for 2025 but will pharma growth be muted by elements beyond its control? In Vivo discusses the headwinds and drivers for pharma in the coming 12 months.

This year has posed substantial challenges for global markets: a prolonged period of high interest rates, ongoing geopolitical instability, democratic uncertainty, and an unprecedented number of national elections affected nearly half of the world’s population. The pharmaceutical industry has responded to this macroenvironment with less dealmaking, instead cherry-picking necessary partnerships while it waits to see how geopolitical upheaval shapes the environment.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Outlook

Outlook 2025: Will Geopolitics Dampen Pharma’s Comeback Party?

 
• By Jo Shorthouse

The financial macroenvironment may be looking more favorable for 2025 but will pharma growth be muted by elements beyond its control? In Vivo discusses the headwinds and drivers for pharma in the coming 12 months.

Biopharma Plumps Pipeline With Healthy Weight Loss Candidates

 
• By Melanie Senior

Despite the stellar success of the class so far, biotech is now looking past GLP-1s to more tolerable, sustainable approaches to obesity.

Benzos to Breakthroughs: Bill Burns on Roche's Transformation

 
• By Jo Shorthouse

Former Roche CEO Bill Burns reflects on transforming Roche into a global leader in specialty care and oncology. Now, as he spearheads efforts to combat antibiotic resistance, Burns shares insights on industry evolution, the power of cultural change, and the urgent need for a new business model in antibiotics development.

Medtech Industry Reaches New Chapter In Its Structural Evolution

 
• By Ashley Yeo

The Top 100 ranking of global medtechs by revenues for 2023 illustrated how the leaders continue to tailor innovation to users and patients according to market trends while driving portfolio management for growth.

More from Growth

Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again

 
• By Eleanor Malone

The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.

In Conversation: Sketching The Future Of Biotech Investment With Lilly Ventures

 
• By Jo Shorthouse

Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.

TechBio’s Next Wave: Where AI Meets Biology And Investment Opportunity

 
• By David Wild

TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.